Literature DB >> 16278774

Vitamin D: a hormone for all seasons--how much is enough?

Howard A Morris1.   

Abstract

Further understanding of its endocrine mechanisms and increased evidence for autocrine/paracrine actions has recently enhanced our knowledge of the biological activities of the vitamin D metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D). The recognition of the contribution of vitamin D depletion to increased risk of osteoporosis, and most importantly the risk of hip fracture in the elderly, has increased the clinical significance of clinical laboratory testing for vitamin D status. Research has revealed that at least three genes contribute to vitamin D activity within tissues. These are the vitamin D receptor as well as two major vitamin D metabolising enzymes, CYP27B1, responsible for synthesis of 1,25(OH)2D and CYP24, responsible for catabolism of vitamin D metabolites. Current research focuses on the contribution of vitamin D metabolism to increasing vitamin D activity. This is of particular interest in bone forming cells where increased 1,25(OH)2D activity has been proposed to contribute to strengthening the skeleton. As well, solid tumours such as prostate, breast and colon cancers are another increasing area of vitamin D research. The major issues for the clinical laboratory in vitamin D testing include defining clinical decision limits for the interpretation of serum 25-hydroxyvitamin D (25OHD) levels and improving the precision and accuracy of this assay.

Entities:  

Year:  2005        PMID: 16278774      PMCID: PMC1240026     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  46 in total

1.  Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency.

Authors:  D Jesudason; A G Need; M Horowitz; P D O'Loughlin; H A Morris; B E C Nordin
Journal:  Bone       Date:  2002-11       Impact factor: 4.398

2.  Seasonal variation of histological osteomalacia in femoral-neck fractures.

Authors:  J E Aaron; J C Gallagher; B E Nordin
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

3.  Letter: Osteomalacia and femoral fractures.

Authors:  J Aaron; J C Gallagher; B E Nordin
Journal:  Lancet       Date:  1974-03-30       Impact factor: 79.321

4.  Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.

Authors:  L H Ly; X Y Zhao; L Holloway; D Feldman
Journal:  Endocrinology       Date:  1999-05       Impact factor: 4.736

5.  Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck.

Authors:  M R Baker; H McDonnell; M Peacock; B E Nordin
Journal:  Br Med J       Date:  1979-03-03

6.  Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.

Authors:  Donna M Peehl; Rajesh Shinghal; Larisa Nonn; Eugene Seto; Aruna V Krishnan; James D Brooks; David Feldman
Journal:  J Steroid Biochem Mol Biol       Date:  2004-10       Impact factor: 4.292

7.  Calcitonin stimulates expression of the rat 25-hydroxyvitamin D3-24-hydroxylase (CYP24) promoter in HEK-293 cells expressing calcitonin receptor: identification of signaling pathways.

Authors:  X-H Gao; P P Dwivedi; J L Omdahl; H A Morris; B K May
Journal:  J Mol Endocrinol       Date:  2004-02       Impact factor: 5.098

8.  Determinants of circulating 1,25-dihydroxyvitamin D3 levels: the role of renal synthesis and catabolism of vitamin D.

Authors:  Paul H Anderson; Peter D O'Loughlin; Brian K May; Howard A Morris
Journal:  J Steroid Biochem Mol Biol       Date:  2004-05       Impact factor: 4.292

9.  Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women.

Authors:  Diane Feskanich; Walter C Willett; Graham A Colditz
Journal:  Am J Clin Nutr       Date:  2003-02       Impact factor: 7.045

10.  Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice.

Authors:  Y C Li; M Amling; A E Pirro; M Priemel; J Meuse; R Baron; G Delling; M B Demay
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  7 in total

1.  Improving the measurement of 25-hydroxyvitamin D.

Authors:  Andrew M Wootton
Journal:  Clin Biochem Rev       Date:  2005-02

2.  Autocrine and paracrine actions of vitamin d.

Authors:  Howard A Morris; Paul H Anderson
Journal:  Clin Biochem Rev       Date:  2010-11

3.  Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Authors:  Wei Luo; Wei-Dong Yu; Yingyu Ma; Mikhail Chernov; Donald L Trump; Candace S Johnson
Journal:  Cancer Res       Date:  2013-01-28       Impact factor: 12.701

4.  Less-calcemic vitamin D analogs enhance creatine kinase specific activity and modulate responsiveness to gonadal steroids in rat skeletal tissues.

Authors:  D Somjen; G H Posner; Y Weisman; A M Kaye
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

5.  Vitamin D status and associated occupational factors in Korean wage workers: data from the 5th Korea national health and nutrition examination survey (KNHANES 2010-2012).

Authors:  Harin Jeong; Sujin Hong; Yunjeong Heo; Hosun Chun; Daeseong Kim; Jongtae Park; Mo-Yeol Kang
Journal:  Ann Occup Environ Med       Date:  2014-09-16

6.  Longitudinal Analysis of 1α,25-dihidroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer.

Authors:  Dorottya Mühl; Magdolna Herold; Zoltan Herold; Lilla Hornyák; Attila Marcell Szasz; Magdolna Dank
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

7.  Serum 25-Hydroxyvitamin D Levels in Pediatric Burn Patients.

Authors:  Behnam Sobouti; Aina Riahi; Shahrzad Fallah; Masoumeh Ebrahimi; Azin Shafiee Sabet; Yaser Ghavami
Journal:  Trauma Mon       Date:  2016-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.